NPM1 and leukemia: Given the efficacy of MIs in preclinical models [125,144,157,170,177,178,179,180,181,182,183,184], multiple MIs are currently undergoing clinical trials in MLLr and NPM1 mutant leukemias (reviewed in [171,172,173,174,175,177,185]), including SNDX-5613, KO-539, JNJ-75276617, DS-1594b, BMF-219, DSP-5336, and BN104 (Table 1 and Table 2).